Oxbow Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Oxbow Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-4,650	Closed	-$431K	–	242
2024 Q2	$431K	Hold	4,650	–	–	0.05%	152
2024 Q1	$441K	Buy	+4,650	New	+$431K	0.06%	135
2023 Q1	–	Sell	-5,850	Closed	-$486K	–	225
2022 Q4	$486K	Hold	5,850	–	–	0.09%	131
2022 Q3	$464K	Hold	5,850	–	–	0.07%	160
2022 Q2	$434K	Hold	5,850	–	–	0.06%	173
2022 Q1	$526K	Buy	5,850 +2,350	+67%	+$217K	0.05%	179
2021 Q4	$392K	Buy	+3,500	New	+$422K	0.04%	212

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Oxbow Advisors's XBI Position: Q3 2024 in Review

Oxbow Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2024, closing a stake of 4,650 shares — an estimated $431K sold.

Oxbow Advisors first reported a position in XBI in Q4 2021 and held it in 7 quarters. The position peaked at $526K in Q1 2022. 769 funds tracked by Wall St. Rank hold XBI as of Q3 2024.

Oxbow Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2024 after selling out during the quarter.
Oxbow Advisors sold 4,650 State Street SPDR S&P Biotech ETF shares in Q3 2024, an estimated $431K.
Oxbow Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2021 and held it in 7 quarters.
Oxbow Advisors's State Street SPDR S&P Biotech ETF position peaked at $526K in Q1 2022.
769 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2024.

Based on Oxbow Advisors's 13F filing for Q3 2024, filed 1 Nov 2024.